Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Prolonging survival in patients with AML ineligible for intensive chemotherapy

Eytan Stein • 16 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia Azacitidine Venetoclax

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to prolong survival in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. He notes the success of combining azacitidine and venetoclax and suggests focusing on adding non-myelosuppressive agents to enhance this combination’s efficacy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eytan Stein

0:56
Promising combinations being explored for IDH1 & IDH2-mutated AML
Eytan Stein • 16 Jun 2024
1:25
Therapeutic targeting of splicing factor mutations in myeloid malignancies
Eytan Stein • 16 Jun 2024
0:47
Tamibarotene combined with azacitidine and venetoclax to treat AML and MDS with RARA abnormalities
Eytan Stein • 16 Jun 2024
1:27
The role of menin inhibitors in the treatment of HR-MDS and AML
Eytan Stein • 5 May 2023

Related Videos

1:59
Phase I study of pevonedistat, azacitidine, and venetoclax in patients with R/R AML
Guru Subramanian Guru Murthy • 11 Jul 2024
1:53
Advancements in prolonging remission post-transplant
Guru Subramanian Guru Murthy • 11 Jul 2024
7:16
Developing a mouse model to elucidate the molecular mechanisms of Richter's transformation
Prajish Iyer • 24 Jul 2024
2:30
Should patients with certain ALL subtypes be considered for alloSCT irrespective of MRD status?
Nicolas Boissel • 15 Jun 2024
The content of VJHemOnc is intended for healthcare professionals